Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs.
| Title | Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. |
| Publication Type | Journal Article |
| Year of Publication | 2000 |
| Authors | John J, Wu MF, Siegel JM |
| Journal | Sleep Res Online |
| Volume | 3 |
| Issue | 1 |
| Pagination | 23-8 |
| Date Published | 2000 |
| ISSN | 1096-214X |
| Keywords | Animals, Behavior, Animal, Carrier Proteins, Cataplexy, Circadian Rhythm, Disease Models, Animal, Dogs, Dose-Response Relationship, Drug, Electroencephalography, Electromyography, Electrooculography, Female, Injections, Intravenous, Intracellular Signaling Peptides and Proteins, Male, Motor Activity, Narcolepsy, Neuropeptides, Orexins, Sleep, Sleep Stages, Treatment Outcome, Wakefulness |
| Abstract | Recent work has implicated the hypocretin (orexin) system in the genesis of narcolepsy. In the current study we demonstrate that systemically administered hypocretin-1 (Hcrt-1) produces an increase in activity level, longer waking periods, a decrease in REM sleep without change in nonREM sleep, reduced sleep fragmentation and a dose dependent reduction in cataplexy in canine narcoleptics. Repeated administration of single daily doses of Hcrt-1 led to consolidation of waking and sleep periods and to a complete loss of cataplexy for periods of three or more days after treatment in animals that were never asymptomatic under control conditions. Systemic administration of Hcrt-1 may be an effective treatment for narcolepsy. |
| Alternate Journal | Sleep Res Online |
| PubMed ID | 11382896 |
| Grant List | HL41370 / HL / NHLBI NIH HHS / United States HL60296 / HL / NHLBI NIH HHS / United States NS14610 / NS / NINDS NIH HHS / United States |
